chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Pyrexia
Clinical narrative: Fever; Chills; headache; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the arm left on 18Mar2021 at 15:00 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included liver transplantation, hypothyroidism, allergy nos, allergy to molds, flagyl allergy and sulfonamide allergy. Concomitant medications included tacrolimus (MANUFACTURER UNKNOWN) from , bupropion hydrochloride (WELLBUTRIN) , calcium levomefolate (DEPLIN) and levothyroxine sodium (SYNTHROID) and more. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the arm left on 25Feb2021 at 15:30 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Mar2021 at 05:30 AM, after 2.5days of the vaccination, the patient experienced fever, chills, headaches and fatigue which lasted 4-5 days and took very long to get over. The events did not result in doctor or other healthcare professional office/clinic visit. Therapeutic measures and treatments were taken as a result of the adverse events included with non steroidal anti inflammatory drugs, tylenol and heat. The clinical outcome of the events fever, chills headache and fatigue was resolved on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Viral test
Clinical narrative: Started feeling a salty after taste on my mouth; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the arm left on 10Mar2021 at 07:30 (at the age of 46-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and migraine headaches. The patient had allergy to benzonatate. Concomitant medication included amlodipine (MANUFACTURER UNKNOWN) 5 milligram (mg). The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was tested for COVID-19. On 13Mar2021 at 09:00, the patient experienced salty taste in her mouth. It was reported that the week after the vaccine, the patient was fine. Everything she ate would taste as if she sprinkled salt on the top. The event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the events. On 14Mar2021, the patient had nasal swab test and the result was negative. The clinical outcome of taste salty was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Oral discomfort, Paraesthesia, Paraesthesia oral
Clinical narrative: Burning/tingling sensation on skin around mouth; Burning/tingling sensation on skinaround mouth; Tingling sensation in legs ankles and feet; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 29Mar2021 at 12:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to maple. Concomitant medications included cefalexin (CEPHALEXIN) at a dose of 500 mg twice daily from an unknown date for an unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021 at 20:15, the patient experienced tingling sensation in legs, ankles and feet and burning/tingling sensation on skin around mouth. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events tingling sensation in legs, ankles and feet and burning/tingling sensation on skin around mouth. The clinical outcomes of the events tingling sensation in legs, ankles and feet and burning/tingling sensation on skin around mouth were unknown at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Swelling face
Clinical narrative: Red face cheeks; Red face cheeks, slightly swollen, notcaused by sun exposure; This is a spontaneous report from a non-contactable consumer, the patient. A 17-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 27Mar2021 at 09:00(at the age of 17-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 28Mar2021, the patient experienced red face cheeks, slightly swollen, not caused by sun exposure. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of red face and swelling of face was not recovered at the time of report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Frequent bowel movements, Headache
Clinical narrative: Headache; Diarrhea; increased bowelmovements; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6206), via an unspecified route of administration in the right arm on 16Mar2021 at 15:00 (at the age of 39-years-old), as a single dose for COVID-19 immunisation. Medical history included depression, migraine, chronic shoulder issue, penicillin allergy and allergy to sulpha. Concomitant medications included galcanezumab (EMGALITY), topiramate (MANUFACTURER UNKNOWN), pregabalin (MANUFACTURER UNKNOWN), bupropion (MANUFACTURER UNKNOWN) and escitalopram oxalate (LEXAPRO); all for unknown indications from unknown dates. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNSPECIFIED) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Mar2021, the patient experienced headache which lasted for two weeks, diarrhea and increased bowel movements, which lasted for several days. The events resulted in doctor or other healthcare professional office/clinic visit. The patient received IMODIUM for bowel movements and prednisone for headache as a treatment. The clinical outcome of the events headache, diarrhea and the increased bowel movements was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Headache, Herpes simplex, Pain, Pyrexia
Clinical narrative: Low fever; Headache; Body ache; Hsv outbreak; Bad mouth tasting; This is a spontaneous report from a non-contactable healthcare professional. A 33-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 30Mar2021(at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, hypertension and hsv. Concomitant medications included metformin (MANUFACTURER UNKNOWN), vildagliptin (MANUFACTURER UNKNOWN) and losartan (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021 at 17:15, the patient had low fever (38.3: Unspecified units), Hsv outbreak, headache, body aches and bad mouth tasting. Therapeutic measure taken for the adverse events included treatment with ZOVIRAX on an unspecified date. The adverse event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcomes of low fever (38.3), Hsv outbreak, headache, body aches and bad mouth tasting were not recovered at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Taste disorder
Clinical narrative: Low fever; Headache; Body ache; Hsv outbreak; Bad mouth tasting; This is a spontaneous report from a non-contactable healthcare professional. A 33-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 30Mar2021(at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, hypertension and hsv. Concomitant medications included metformin (MANUFACTURER UNKNOWN), vildagliptin (MANUFACTURER UNKNOWN) and losartan (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021 at 17:15, the patient had low fever (38.3: Unspecified units), Hsv outbreak, headache, body aches and bad mouth tasting. Therapeutic measure taken for the adverse events included treatment with ZOVIRAX on an unspecified date. The adverse event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcomes of low fever (38.3), Hsv outbreak, headache, body aches and bad mouth tasting were not recovered at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary mass, Lymphadenopathy
Clinical narrative: Purple small lump inside armpit; Swollen lymph gland under left arm; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER2413) via unspecified route of administration in the left arm on 24Mar2021 at 11:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. The patient medical history included hypothyroidism, asthma. The patient had a known allergy to doyxcylene. The patient concomitant medication included leyvothroxine sodium (SYNTHROID) received within 2 weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EL9262) via unspecified route of administration in the left arm on 04Mar2021 at 15:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19.  Since the vaccination, the patient had not tested for COVID-19. On 26Mar2021 at 12:00, the patient experienced swollen lymph gland under left arm and after a week plus days of second shot of vaccination, the patient experienced purple small lump inside armpit. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of swollen lymph glands and axillary lump. The clinical outcome of the events swollen lymph glands and axillary lump was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia
Clinical narrative: Right foot fell asleep; This is a spontaneous report from a non-contactable consumer, the patient. A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration in the left arm on 31Mar2021(at the age of 39-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included birth control pills (MANUFACTURER UNKNOWN) for unspecified indication from unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021, on date of injection, the patient right foot "fell asleep" throughout the day, it was relieved when the patient got up and walked around but reoccurred when seated for an extended period of time. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the event paraesthesia foot was unknown at the time of reporting.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Cold sweat, Fatigue, Feeling abnormal, Neuralgia
Clinical narrative: Sore arm; Nerve pain downarm into wrist.; Brain fog; Clammy hands; tired clammy hands; Stomach upset; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Ep7534) via an unspecified route of administration in the left arm on 15Mar2021 at 10:15 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included Reynaud's, osteoarthritis, irritable bowel syndrome. Allergies to medications included penicillin, ampicillin, clindamycin and erythromycin. Concomitant medications received within 2 weeks of vaccination included vitamin (MANUFACTURER UNKNOWN), multivitamin (MANUFACTURER UNKNOWN), omega (MANUFACTURER UNKNOWN), turmeric (MANUFACTURER UNKNOWN) and probiotics (MANUFACTURER UNKNOWN). The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 15Mar2021 at 10:15, the patient experienced sore arm, nerve pain down arm into wrist, days after and continuing over two weeks brain fog, tired, clammy hands and upset stomach. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Treatment received for the adverse events was reported as no. The clinical outcome of the events sore arm, nerve pain down arm into wrist, days after and continuing over two weeks brain fog, tired, clammy hands and upset stomach were resolved with lasting effects.  No follow-ups attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Sore arm; Nerve pain downarm into wrist.; Brain fog; Clammy hands; tired clammy hands; Stomach upset; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Ep7534) via an unspecified route of administration in the left arm on 15Mar2021 at 10:15 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included Reynaud's, osteoarthritis, irritable bowel syndrome. Allergies to medications included penicillin, ampicillin, clindamycin and erythromycin. Concomitant medications received within 2 weeks of vaccination included vitamin (MANUFACTURER UNKNOWN), multivitamin (MANUFACTURER UNKNOWN), omega (MANUFACTURER UNKNOWN), turmeric (MANUFACTURER UNKNOWN) and probiotics (MANUFACTURER UNKNOWN). The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 15Mar2021 at 10:15, the patient experienced sore arm, nerve pain down arm into wrist, days after and continuing over two weeks brain fog, tired, clammy hands and upset stomach. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Treatment received for the adverse events was reported as no. The clinical outcome of the events sore arm, nerve pain down arm into wrist, days after and continuing over two weeks brain fog, tired, clammy hands and upset stomach were resolved with lasting effects.  No follow-ups attempts are needed. No further information is expected.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Diarrhoea, Headache, Nausea, Pyrexia, Vomiting
Clinical narrative: severe nausea; severe vomiting; fever; headache; diarrhea; This is a spontaneous report from a contactable other healthcare professional. A 48-years-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via intramuscular route of administration on 27Mar2021 at 14:00 (at the age of 48-year-old), as a single dose for COVID-19 immunisation. No medical history was reported. The patient had no allergies to medications, food, or other products. Concomitant medications included emtricitabine, tenofovir alafenamide fumarate (DESCOVY), for unknown indication from unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via intramuscular route of administration on 06Mar2021 at 14:00 (at the age of 48-year-old), as a single dose for COVID-19 immunisation.  The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 29Mar2021 at 17:00, the patient experienced severe nausea, and vomiting 48 hours after vaccine, fever, headache and diarrhea. Therapeutic measures were taken as a result of events and included treatment with ZOFRAN, TYLENOL, rest, oral hydration. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of events, severe nausea, vomiting, fever, headache and diarrhea were not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Pain in extremity
Clinical narrative: Sore arm; Headache; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3247), via an unspecified route of administration in the right arm on 29Mar2021 at 10:45 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history and concomitant medications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3247), via an unspecified route of administration in the left arm on 08Mar2021 at 11:00 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021 at 08:00, the patient experienced sore arm, headache and fatigue. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events sore arm, headache and fatigue were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Rash erythematous, Skin warm
Clinical narrative: From the injection sight down to almost elbow and going side to side a solid red rash; solid red rash that was hot to the touch; This is a spontaneous report from a contactable consumer, the patient. A 61-years-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 28Mar2021 at 08:45 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, blood pressure high and overweight from an unspecified date. The patient was allergic to soy. The patient received other medications (unspecified) within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 28Mar2021 at 20:00, the patient reported that from the injection sight down to almost elbow and going side to side a solid red rash, that was hot to the touch and the area covered was size of her hand. The patient did not receive any treatment for the event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of from the injection sight down to almost elbow and going side to side a solid red rash and solid red rash that was hot to the touch was not resolved at the time of reporting.  No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Diarrhoea
Clinical narrative: Watery Diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8730) via an unspecified route of administration in the right arm on 28Mar2021 at 12:15 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6206) via an unspecified route of administration in the right arm on 07Mar2021 at 14:30 (at the age of 48 years) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 28Mar2021 at 20:30, the patient experienced watery diarrhea. The patient did not receive any treatment for the event. The clinical outcome of the event watery diarrhea was recovered on an unknown date at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Vaccination site pain
Clinical narrative: vaccination sight pain; nausea; This is a spontaneous report received from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: CN6207) via an unspecified route of administration in the left arm on 30Mar2021 at 13:15 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. The patient medical history included asthma. The patient was allergic to fruit allergy(kiwi). The patient had drug allergy while taking erythromycin (MANIFACTURER UNKNOWN). Concomitant medications included rosuvastatin (MANUFACTURER UNKNOWN) for unknown indication, levothyroxine (MANUFACTURER UNKNOWN) for unknown indication, ibuprofen sodium (IBUPROFEN) for unknown indication and ascorbic acid (VITAMIN C) for unknown indication. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 31Mar2021 at 07:00, the patient experienced injection sight pain and nausea. The adverse events did not result in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the reported events. The clinical outcome of the events vaccination sight pain and nausea was recovering at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Fatigue, Nausea, Pain in jaw, Sinus headache
Clinical narrative: Moderate pain at injection site; Severe sinus headache; pain in jaw; nausea; upset stomach; fatigue; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 30Mar2021 at 16:15 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 31Mar2021 at 12:00, the patient experienced moderate pain at injection site, severe sinus headache, pain in jaw, nausea, upset stomach and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events included treatment with acetaminophen. The clinical outcome of the moderate pain at injection site, severe sinus headache, pain in jaw, nausea, upset stomach and fatigue was resolving at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Moderate pain at injection site; Severe sinus headache; pain in jaw; nausea; upset stomach; fatigue; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 30Mar2021 at 16:15 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 31Mar2021 at 12:00, the patient experienced moderate pain at injection site, severe sinus headache, pain in jaw, nausea, upset stomach and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events included treatment with acetaminophen. The clinical outcome of the moderate pain at injection site, severe sinus headache, pain in jaw, nausea, upset stomach and fatigue was resolving at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Paraesthesia
Clinical narrative: slight tingling in my left cheek on my face; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old male patient received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: UNKNOWN), via an unspecified route of administration in the left arm on 24Feb2021 at 09:30 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Medical history included shellfish allergy and gluten intolerance. The patient did not receive any other medications within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 24Feb2021 at 10:00 the patient experienced slight tingling in left cheek and on face which was reminiscent of allergic reaction to shellfish. The patient did not receive any treatment for the event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of tingling was recovered on an unknown date.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Heavy menstrual bleeding
Clinical narrative: Heavy menstrual bleeding; Period much longer than normal; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 28Mar2021 at 12:00 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history included endometriosis, hypertension. The patient was allergic to pineapple fruit. Concomitant medication included amlodipine (MANUFACTURER UNKNOWN) amlodipine besilate (BESYLON) and norethisterone (NORETHINDRONE) for unknown indication. The patient previously took BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 07Mar2021 at 12:00 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021 at 04:00, the patient experienced very heavy menstrual bleeding with a lot of blood clots, period was much longer than normal. The patient did not receive any treatment for the event. The event resulted in doctor or other healthcare professional office or clinic visit. The clinical outcome of the event heavy menstrual bleeding, prolonged periods was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pain in extremity
Clinical narrative: Pain in left arm; Fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 33-years-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration in the left arm on 29Mar2021 at 09:00 (at the age of 33-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration on 09Mar2021 at 14:00 (at the age of 33-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 29Mar2021 at 19:00 the patient experienced pain in left arm and fatigue. The clinical outcomes of the events pain in left arm and fatigue were unknown at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Headache, Pain
Clinical narrative: Aches; chills; pain in right arm; fever of 101.5; Extreme fatigue; Headache; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the right arm on 29Mar2021 at 13:15 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and known allergy to amoxicillin. Concomitant medication included vitamin d (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date.  The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 08Mar2021 at 13:15 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination the patient had not been tested for COVID-19. Body temperature as recorded on 30Mar2021 was 101.5 (Unspecified units). On 30Mar2021 at 12:00, the patient experienced aches, chills, pain in right arm, fever of 101.5, extreme fatigue and headache. The patient had a headache a day before, but most symptoms started that day. No therapeutic measures were taken as a result of the adverse events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of general body pains, chills, pain in arm, fever, fatigue and headache was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Pyrexia
Clinical narrative: Aches; chills; pain in right arm; fever of 101.5; Extreme fatigue; Headache; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the right arm on 29Mar2021 at 13:15 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and known allergy to amoxicillin. Concomitant medication included vitamin d (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date.  The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 08Mar2021 at 13:15 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination the patient had not been tested for COVID-19. Body temperature as recorded on 30Mar2021 was 101.5 (Unspecified units). On 30Mar2021 at 12:00, the patient experienced aches, chills, pain in right arm, fever of 101.5, extreme fatigue and headache. The patient had a headache a day before, but most symptoms started that day. No therapeutic measures were taken as a result of the adverse events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of general body pains, chills, pain in arm, fever, fatigue and headache was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Jaw clicking, Pain in jaw
Clinical narrative: Pain in jaw; Popping in jaw; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on an unknown date in Mar2021 at 07:45 (at the age of 49-year-old) as a single dose for COVID-19 immunisation. The patient's medical history included temporomandibular joint disorder (TMJ), hypersomnia and anxiety. The patient's concomitant medications included methylphenidate (MANUFACTURER UNKNOWN), citalopram (MANUFACTURER UNKNOWN), multivitamins (MANUFACTURER UNKNOWN) and cetirizine hydrochloride (ZYRTEC); all from unknown dates for unknown indications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient took BIAXIN in the past and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 22Mar2021 at 10:00, the patient experienced pain and popping in jaw. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcomes of the events pain and popping in jaw was recovered with lasting effects.   No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Breast abscess, Peripheral swelling
Clinical narrative: developed abscess on left breast within a week or two.; swelling to left axilla; This is a spontaneous report from a contactable nurse, the patient. A 63-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: en6201) via an unspecified route of administration in the left arm on 13Feb2021 at 11.00 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes mellitus. The patient did not have allergies to medications, food, or other products. Concomitant medications included acebutolol (ACEBUALOL), cetirizine hydrochloride (ZYRTEC), fluticasone propionate (FLOVENT). The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: el9263) via an unspecified route of administration in the left arm on 23Jan2021 at 16:00 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccine in four weeks prior to COVID-19 vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 21Feb2021 at 13.00, the patient experienced an abscess developed on left breast within a week or two and swelling to left axilla. The patient received antibiotics (unspecified) as therapeutic measures for the reported events. The events resulted in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  The clinical outcome of the events abscess on left breast and swelling to left axilla was not resolved at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Dysstasia, Gait disturbance, Hypoaesthesia, Paraesthesia, Vision blurred
Clinical narrative: blurry vision; Could not stand or walk for more than 1-2 mins without discomfort; Could not stand or walk for more than 1-2 mins without discomfort; Tingling sensation from the back ofboth knees, down to the feet & toes; numbing; Feels likes pins & needles; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 29Mar2021 at 09:00 as a single dose (at the age of 53-year-old) for COVID-19 immunisation. The medical history of the patient included type II diabetes mellitus. The patient reported no allergies to medications, food, or other products. Concomitant medications included metformin hydrochloride (METFORMIN), rosuvastatin calcium (CRESTOR), ascorbic acid (ESTER-C), colecalciferol (VITAMIN D3). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021 at 14:00, the patient experienced tingling sensation from the back of both knees, down to the feet & toes, felt likes pins and needles and numbing and was not able to stand or walk for more than 1-2 mins without discomfort, even when sitting down, having both feet down on the ground. Had to be in a lying position or raised leg/feet position to feel relief. Also noticed blurry vision on 30Mar2021, the following day of administering the vaccine, even with his reading glasses on. No other unusual discomfort or adverse effect was noted that time. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the events of tingling sensation, pins and needles, numbing, blurry vision. The clinical outcome of tingling sensation, pins and needles, numbing, blurry vision walking difficulty and difficulty in standing was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Nausea, Pyrexia, Swelling face
Clinical narrative: Facial Swelling; Fever; Headache; Nausea; This is a spontaneous report from a non-contactable consumer, the patient. A 41-years-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in Mar2021 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications were not reported. The patient had previously received penicillin (MANUFACTURER UNKNOWN) and experienced allergy. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date in Mar2021, the patient experienced facial swelling, fever, headache and nausea. The patient did not receive any treatment for the adverse events. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events facial swelling, fever, headache and nausea were resolving at the time of this report.  No follow-up attempts are possible; information about lot number cannot be obtained
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Abnormal dreams, Arthralgia, Body temperature, Fatigue, Headache
Clinical narrative: Sore arm; Tiredness; Arthralgia; myalgia; fever; headache; strange dreams; Nausea; swollen gland (neck); This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6203) via an unspecified route of administration in the right arm on 09Mar2021 at 16:15 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Medical history included hypertension and gluten allergy (Gluten sensitivity). Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL9264) via an unspecified route of administration in the right arm on 16Feb2021 at 16:45 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient had not received other vaccines within four weeks prior to the COVID-19 vaccine. On 10Mar2021 at 01:00, the patient experienced sore arm, tiredness, arthralgia, myalgia, fever, headache, strange dreams (bizarre dreams), nausea and swollen gland in neck (gland in neck). The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome for the events sore arm, tiredness, arthralgia, myalgia, fever, headache, vivid dreams, nausea and gland in neck was resolved on unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Myalgia, Nausea, Pain in extremity, Pyrexia
Clinical narrative: Sore arm; Tiredness; Arthralgia; myalgia; fever; headache; strange dreams; Nausea; swollen gland (neck); This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6203) via an unspecified route of administration in the right arm on 09Mar2021 at 16:15 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Medical history included hypertension and gluten allergy (Gluten sensitivity). Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL9264) via an unspecified route of administration in the right arm on 16Feb2021 at 16:45 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient had not received other vaccines within four weeks prior to the COVID-19 vaccine. On 10Mar2021 at 01:00, the patient experienced sore arm, tiredness, arthralgia, myalgia, fever, headache, strange dreams (bizarre dreams), nausea and swollen gland in neck (gland in neck). The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome for the events sore arm, tiredness, arthralgia, myalgia, fever, headache, vivid dreams, nausea and gland in neck was resolved on unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.